PET Findings of Intramedullary Tumors of the Spinal Cord Using [¹⁸F] FDG and [¹¹C] Methionine

REFERENCES

1. 1.↵
   1. Borgwardt L,
   2. Højgaard L,
   3. Carstensen H,
   4. et al

   . Increased fluorine-18–2-fluoro-2-deoxy-D-glucose (FDG) uptake in childhood CNS tumors is correlated with malignancy grade: a study with FDG positron emission tomography/magnetic resonance imaging coregistration and image fusion. J Clin Oncol 2005;23:3030–37

   Abstract/FREE Full Text
2. 2.↵
   1. Choi SJ,
   2. Kim JS,
   3. Kim JH,
   4. et al

   . [18F]3′-deoxy-3′-fluorothymidine PET for the diagnosis and grading of brain tumors. Eur J Nucl Med Mol Imaging 2005;32:653–59

   CrossRefPubMed
3. 3.↵
   1. Tsuchida T,
   2. Takeuchi H,
   3. Okazawa H,
   4. et al

   . Grading of brain glioma with 1-¹¹C-acetate PET: comparison with ¹⁸F-FDG PET. Nucl Med Biol 2008;35:171–76

   CrossRefPubMed
4. 4.↵
   1. Hustinx R,
   2. Pourdehnad M,
   3. Kaschten B,
   4. et al

   . PET imaging for differentiating recurrent brain tumor from radiation necrosis. Radiol Clin North Am 2005;43:35–47

   CrossRefPubMed
5. 5.↵
   1. Terakawa Y,
   2. Tsuyuguchi N,
   3. Iwai Y,
   4. et al

   . Diagnostic accuracy of ¹¹C-methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy. J Nucl Med 2008;49:694–99

   Abstract/FREE Full Text
6. 6.↵
   1. Kim YH,
   2. Oh SW,
   3. Lim YJ,
   4. et al

   . Differentiating radiation necrosis from tumor recurrence in high-grade gliomas: assessing the efficacy of ¹⁸F-FDG PET, ¹¹C-methionine PET and perfusion MRI. Clin Neurol Neurosurg 2010;112:758–65

   CrossRefPubMed
7. 7.↵
   1. Tan H,
   2. Chen L,
   3. Guan Y,
   4. et al

   . Comparison of MRI, F-18 FDG, and C-11 choline PET/CT for their potentials in differentiating brain tumor recurrence from brain tumor necrosis following radiotherapy. Clin Nucl Med 2011;36:978–81

   CrossRefPubMed
8. 8.↵
   1. Wong TZ,
   2. van der Westhuizen GJ,
   3. Coleman RE

   . Positron emission tomography imaging of brain tumors. Neuroimaging Clin N Am 2002;12:615–26

   CrossRefPubMedWeb of Science
9. 9.↵
   1. Salaun PY,
   2. Gastinne T,
   3. Bodet-Milin C,
   4. et al

   . Analysis of ¹⁸F-FDG PET diffuse bone marrow uptake and splenic uptake in staging of Hodgkin's lymphoma: a reflection of disease infiltration or just inflammation? Eur J Nucl Med Mol Imaging 2009;36:1813–21

   CrossRefPubMed
10. 10.↵
    1. Smeets P,
    2. Ham H,
    3. Ceelen W,
    4. et al

    . Differentiation between peri-anastomotic inflammatory changes and local recurrence following neoadjuvant radiochemotherapy surgery for colorectal cancer using visual and semiquantitative analysis of PET-CT data. Q J Nucl Med Mol Imaging 2010;54:327–32

    PubMed
11. 11.↵
    1. Zhao S,
    2. Kuge Y,
    3. Kohanawa M,
    4. et al

    . Usefulness of ¹¹C-methionine for differentiating tumors from granulomas in experimental rat models: a comparison with ¹⁸F-FDG and ¹⁸F-FLT. J Nucl Med 2008;49:135–41

    Abstract/FREE Full Text
12. 12.↵
    1. Phi JH,
    2. Paeng JC,
    3. Lee HS,
    4. et al

    . Evaluation of focal cortical dysplasia and mixed neuronal and glial tumors in pediatric epilepsy patients using ¹⁸F-FDG and ¹¹C-methionine PET. J Nucl Med 2010;51:728–34

    Abstract/FREE Full Text
13. 13.↵
    1. Kawai N,
    2. Miyake K,
    3. Yamamoto Y,
    4. et al

    . Use of ¹¹C-methionine positron emission tomography in basal germinoma: assessment of treatment response and residual tumor. Childs Nerv Syst 2009;25:845–53

    CrossRefPubMed
14. 14.↵
    1. Piroth MD,
    2. Pinkawa M,
    3. Holy R,
    4. et al

    . Prognostic value of early [¹⁸F]fluoroethyltyrosine positron emission tomography after radiochemotherapy in glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2011;80:176–84

    CrossRefPubMed
15. 15.↵
    1. Palma P,
    2. Conde-Muino R,
    3. Rodriguez-Fernandez A,
    4. et al

    . The value of metabolic imaging to predict tumour response after chemoradiation in locally advanced rectal cancer. Radiat Oncol 2010;5:119

    CrossRefPubMed
16. 16.↵
    1. Aukema TS,
    2. Kappers I,
    3. Valdes Olmos RA,
    4. et al

    . Is ¹⁸F-FDG PET/CT useful for the early prediction of histopathologic response to neoadjuvant erlotinib in patients with non-small cell lung cancer? J Nucl Med 2010;51:1344–48

    Abstract/FREE Full Text
17. 17.↵
    1. Singnurkar A,
    2. Solomon SB,
    3. Gönen M,
    4. et al

    . ¹⁸F-FDG PET/CT for the prediction and detection of local recurrence after radiofrequency ablation of malignant lung lesions. J Nucl Med 2010;51:1833–40

    Abstract/FREE Full Text
18. 18.↵
    1. Kapoor V,
    2. McCook BM,
    3. Torok FS

    . An introducing to PET-CT imaging. Radiographics 2004;24:523–43

    CrossRefPubMedWeb of Science
19. 19.↵
    1. Di Chiro G,
    2. Edward O,
    3. Bairamian E,
    4. et al

    . Metabolic imaging of the brain stem and spinal cord: studies with positron emission tomography using ¹⁸F-2-deoxyglucose in normal and pathological cases. J Comput Assist Tomogr 1983;7:937–45

    CrossRefPubMedWeb of Science
20. 20.↵
    1. Higano S,
    2. Shishido F,
    3. Nagashima M,
    4. et al

    . PET evaluation of spinal cord tumor using ¹¹C-methionine. J Comput Assist Tomogr 1990;14:297–99

    PubMedWeb of Science
21. 21.↵
    1. Alavi A,
    2. Kramer E,
    3. Wegener W,
    4. et al

    . Magnetic resonance and fluorine-18 deoxyglucose imaging in the investigation of a spinal cord tumor. J Nucl Med 1990;31:360–64

    FREE Full Text
22. 22.↵
    1. Sasajima T,
    2. Mineura K,
    3. Itoh Y,
    4. et al

    . Spinal cord ependymoma: a positron emission tomographic study with (¹¹C-methyl)-L-methionine. Neuroradiology 1996;38:53–55

    CrossRefPubMedWeb of Science
23. 23.↵
    1. Meltzer CC,
    2. Townsend DW,
    3. Kottapally S,
    4. et al

    . FDG imaging of spinal cord primitive neuroectodermal tumor. J Nucl Med 1998;39:1207–09

    Abstract/FREE Full Text
24. 24.↵
    1. Wilmshurst JM,
    2. Barrington SF,
    3. Pritchard D,
    4. et al

    . Positron emission tomography in imaging spinal cord tumors. J Child Neurol 2000;15:465–72

    Abstract/FREE Full Text
25. 25.↵
    1. Shimizu T,
    2. Saito N,
    3. Aihara M,
    4. et al

    . Primary spinal oligoastrocytoma: a case report. Surg Neurol 2004;61:77–81

    CrossRefPubMed
26. 26.↵
    1. D'Souza MM,
    2. Sharma R,
    3. Tripathi M,
    4. et al

    . Unusual diagnosis of von Hippel Lindau syndrome on PET/CT. Case report and brief review of literature. Iran J Nucl Med 2009;17:50–54
27. 27.↵
    1. Herzog H,
    2. Van Den Hoff J

    . Combined PET/MR systems: an overview and comparison of currently available options. Q J Nucl Med Mol Imaging 2012;56:247–67

    PubMed
28. 28.↵
    1. Jacobs AH,
    2. Thomas A,
    3. Kracht LW,
    4. et al

    . ¹⁸F-fluoro-L-thymidine and ¹¹C-methylmethionine as markers of increased transport and proliferation in brain tumors. J Nucl Med 2005;46:1948–58

    Abstract/FREE Full Text
29. 29.↵
    1. Viel T,
    2. Talasila KM,
    3. Monfared P,
    4. et al

    . Analysis of the growth dynamics of angiogenesis-dependent and –independent experimental glioblastomas by multimodal small-animal PET and MRI. J Nucl Med 2012;53:1135–45

    Abstract/FREE Full Text
30. 30.↵
    1. Kracht LW,
    2. Friese M,
    3. Herholz K,
    4. et al

    . Methyl-[¹¹C]-methyonine uptake as measured by positron emission tomography correlates to microvessel density in patients with glioma. Eur J Nucl Med Mol Imaging 2003;30:868–73

    CrossRefPubMed
31. 31.↵
    1. Thie JA

    . Understanding the standardized uptake value, its methods, and implications for usage. J Nucl Med 2004;45:1431–34

    FREE Full Text
32. 32.↵
    1. Gumprecht H,
    2. Grosu AL,
    3. Souvatsoglou M,
    4. et al

    . ¹¹C-methionine positron emission tomography for preoperative evaluation of suggestive low-grade gliomas. Zentralbl Neurochir 2007;68:19–23

    CrossRefPubMedWeb of Science
33. 33.↵
    1. Kato T,
    2. Shinoda J,
    3. Oka N,
    4. et al

    . Analysis of 11C-methionine uptake in low-grade gliomas and correlation with proliferative activity. AJNR Am J Neuroradiol 2008;29:1867–71

    Abstract/FREE Full Text
34. 34.↵
    1. Kawase Y,
    2. Yamamoto Y,
    3. Kameyama R,
    4. et al

    . Comparison of ¹¹C-methionine PET and ¹⁸F-FDG PET in patients with primary central nervous system lymphoma. Mol Imaging Biol 2011;13:1284–89

    CrossRefPubMed
35. 35.↵
    1. Fassett DR,
    2. Pingree J,
    3. Kestle JR

    . The high incidence of tumor dissemination in myxopapillary ependymoma in pediatric patients: report of five cases and review of the literature. J Neurosurg 2005;102:59–64

    CrossRefPubMed
36. 36.↵
    1. Morooka M,
    2. Ito K,
    3. Kubota K,
    4. et al

    . ¹¹C-choline and F-18 FDG PET/CT images of hemangioblastoma. Clin Nucl Med 2011;36:143–44

    CrossRefPubMed
37. 37.↵
    1. Powers WJ

    . Intracerebral hemorrhage and head trauma and common effects and common mechanisms of injury. Stroke 2010;41(10 suppl):S107–10

    Abstract/FREE Full Text
38. 38.↵
    1. Allyson R,
    2. Zazulia AR,
    3. Videen TO,
    4. et al

    . Transient focal increase in perihematomal glucose metabolism after acute human intracerebral hemorrhage. Stroke 2009;40:1638–43

    Abstract/FREE Full Text
39. 39.↵
    1. Bleeker-Rovers CP,
    2. Vos FJ,
    3. Corstens HM,
    4. et al

    . Imaging of infectious disease using [¹⁸F]fluorodeoxyglucose PET. Q J Nucl Med Mol Imaging 2008;52:17–29

    PubMed